Back Avineuro Pharmaceuticals, Inc.
A Global Neuroscience Research And Development Company Developing novel small molecules to treat unmet medical needs in the neurological and psychiatric fields.
Avineuro Pharmaceuticals, Inc. reports positive Phase I clinical trial results on AVN-211, potent small molecule for treatment of schizophrenia.
San Diego, CA –May 18th, 2009
Avineuro Pharmaceuticals, Inc. reported today clinical Phase I results on AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. AVN-211 was well tolerated and no adverse events were observed. The compound demonstrated excellent exposure and half-life of more than 15 hours. Avineuro Pharmaceuticals, Inc. plans to start Phase II clinical trials with AVN-211 in schizophrenia next month. Avineuro Pharmaceuticals, Inc. will present this data at ICAD 2009 in Vienna, Austria in July.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
Contact:
Yan Lavrovsky, CEO
Avineuro Pharmaceuticals, Inc.
6605 Nancy Ridge Drive, Suite 126
San Diego, CA 92121
Tel 858-436-1537 / 858-436-1540
Fax 858-228-9798
Email: YLavrovsky@avineuro.com